Eosinophilic fasciitis (EF) is a fibrosing disorder characterized by edema, erythema, and induration of the extremities. Eosinophilic fasciitis can cause substantial morbidity from joint contractures, and permanent fibrosis may ensue without timely treatment.1 Corticosteroids are considered first-line therapy; however, long-term treatment with corticosteroid-sparing agents is required to avoid sequelae of chronic steroid use and achieve a durable clinical response.2 Although methotrexate is often considered the first-line corticosteroid-sparing agent for EF, there is no standardized treatment ladder.1,3 To our knowledge, 3 cases of EF have reported favorable outcomes with mycophenolate mofetil (MMF) to date.3,4 Given the paucity of data, we investigated the clinical response of EF to MMF in 3 tertiary care centers.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tkachenko E, Steuer AB, Lo K, et al. Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers. JAMA Dermatol. 2020;156(5):595–597. doi:10.1001/jamadermatol.2020.0120
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: